* Harvard Bioscience Inc HBIO.OQ HBIO.O is expected
to show a
rise in quarterly revenue when it reports results
* The Holliston Massachusetts-based company is expected to
report
a 4.1% increase in revenue to $28.023 million from $26.92
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
* Refinitiv's mean analyst estimate for Harvard Bioscience
Inc is
for earnings of 4 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Harvard
Bioscience Inc is $7, above its last closing price of $4.30.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 0.07 0.06 0.04 Missed -36.8
Mar. 31 2023 0.05 0.05 0.06 Beat 20
Dec. 31 2022 0.08 0.03 0.04 Beat 20
Sep. 30 2022 0.07 0.07 -0.01 Missed -115
Jun. 0.04 0.06 0.05 Missed -16.7
30 2022
Mar. 31 2022 0.05 0.05 0.04 Missed -25
Dec. 31 2021 0.08 0.10 0.08 Missed -20
Sep. 30 2021 0.06 0.06 0.06 Met 0
This summary was machine generated November 3 at 15:47 GMT. All
figures in US dollars unless otherwise stated